文献速递膀胱癌与上尿路尿路上皮癌

尿路癌患者胚系基因变异发生率及其与结局的关联

Incidence of Germline Genetic Variants in Patients with a Urinary Tract Cancer and Association with Outcomes.
PubMed 文献 · Eur Urol Oncol · 2026-08-13

该回顾性研究在273例尿路癌患者中检测78个已知癌症易感基因的胚系致病变异,并在5972例独立队列中验证频率。结果显示9.3-9.5%的患者携带癌症易感基因变异,现有指南会漏诊超过三分之一的患者;Lynch综合征和DDR变异患者对免疫检查点抑制剂或铂类化疗的应答需进一步研究。

要点

  • 未选择尿路癌队列中9.3-9.5%携带癌症易感基因胚系致病变异。
  • 现有指南会漏诊超过三分之一的胚系致病变异携带者。
  • Lynch综合征和DDR变异患者对ICI或铂类化疗的应答需进一步验证。

核心结论

  • 尿路癌患者中胚系致病变异发生率具有临床意义,现有指南漏诊超过三分之一。
  • Lynch综合征尿路癌对免疫检查点抑制剂的应答及DDR变异对铂类化疗的应答为假设生成性,需进一步研究。

研究设计与样本

  • 回顾性研究,在273例膀胱、肾盂、输尿管和/或尿道尿路癌患者中检测78个已知癌症易感基因的胚系致病变异。
  • 在5972例独立患者队列中验证变异频率,并分析胚系全外显子组测序中在尿路癌中过度代表的变异。
  • 评估变异与治疗相关结局的关联。

主要发现

  • 未选择队列中9.3-9.5%的尿路癌患者携带癌症易感基因的致病/可能致病变异。
  • 无临床人口学变量可预测致病/可能致病变异的存在。
  • Lynch综合征见于0.7-0.8%的患者,更可能患有上尿路疾病并有强烈的个人和家族恶性肿瘤史。
  • 非Lynch DDR变异发生于6.6-8.0%的患者,最常见于CHEK2、BRCA1、BRCA2和ATM。
  • 小队列中Lynch综合征尿路癌对ICI应答良好,DDR变异尿路癌对铂类化疗应答良好。

关键数值与推荐

  • 未选择队列中9.3-9.5%携带癌症易感基因胚系致病变异。
  • Lynch综合征发生率0.7-0.8%,非Lynch DDR变异发生率6.6-8.0%。
  • 现有指南漏诊超过三分之一的胚系致病变异携带者。
  • 标准变异检测方法可能遗漏大片段缺失。

临床怎么用

  • 对尿路癌患者应考虑胚系基因检测,尤其上尿路癌及有强烈个人/家族恶性肿瘤史者。
  • Lynch综合征相关尿路癌可考虑免疫检查点抑制剂治疗。
  • DDR变异相关尿路癌可考虑铂类化疗。
  • 标准变异检测需注意大片段缺失可能被遗漏。

局限性

  • Lynch综合征和DDR变异患者样本量很小,治疗应答结果仅为假设生成性。
  • 标准变异检测方法可能遗漏大片段缺失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Lynch syndrome (LS) and germline DNA damage repair (DDR) mutations have been described in urothelial carcinoma (UC). However, the incidence in unselected cohorts and the impact on outcomes remain unclear. DESIGN: We performed a retrospective study to determine the frequency of pathogenic/likely pathogenic (P/LP) germline variants in 78 known cancer predisposition genes among 273 patients with urinary tract cancer (UTC) of the bladder, renal pelvis, ureter, and/or urethra and validated the frequency in an independent cohort of 5972 patients. We identified variants in germline whole-exome sequencing that were overrepresented in UTC. We measured associations with treatment-related outcomes. RESULTS AND LIMITATIONS: In unselected cohorts, 9.3-9.5% of the patients with UTC harbored a variant in a cancer predisposition gene. No clinicodemographic variable predicted the presence of a P/LP variant. LS was found in 0.7-0.8% of the patients who were more likely to have upper tract disease and strong personal and family histories of malignancy. Non-Lynch DDR variants occurred in 6.6-8.0% of the patients, most often in CHEK2, BRCA1, BRCA2, and ATM. Very small cohorts of patients with UC and LS or a DDR variant responded well to immune checkpoint inhibitors (ICIs) or platinum chemotherapy, respectively. Standard variant calling methods may miss large deletions. CONCLUSIONS: The incidence of P/LP germline variants in UTC is clinically meaningful, and more than one-third of the patients are missed with current guidelines. The response of UC with LS to ICI and with DDR to platinum is hypothesis generating and warrants further investigation.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Kamau K, Byrne L, Goradia R, et al. Incidence of Germline Genetic Variants in Patients with a Urinary Tract Cancer and Association with Outcomes. Eur Urol Oncol. 2026. PMID: 42595653. doi:10.1016/j.euo.2026.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。